Avital Harari1, Ning Li, Michael W Yeh. 1. University of California, Los Angeles, Section of Endocrine Surgery (A.H., M.W.Y.) and Department of Biomathematics (N.L.), Los Angeles, California 90095.
Abstract
CONTEXT: Racial/ethnic minorities suffer disproportionate morbidity and mortality from chronic diseases. OBJECTIVE: Our objective was to assess racial and socioeconomic status (SES) disparities in well-differentiated thyroid cancer (WDTC) patients. DESIGN AND PARTICIPANTS: We conducted a retrospective cohort study on 25 945 patients with WDTC (1999-2008) from the California Cancer Registry (57% white, 4% black, 24% Hispanic, and 15% Asian-Pacific Islander [API]). MAIN OUTCOMES: We evaluated effect of race and SES variables on stage of cancer presentation and overall/disease-specific survival. RESULTS: Significant differences in stage of presentation between all racial groups were found (P<.001), with minority groups presenting with a higher percentage of metastatic disease as compared with white patients (black, odds ratio [OR]=1.36 with confidence interval [CI] 1.01-1.84; Hispanic, OR=1.89 [CI, 1.62-2.21], API, OR=1.82 [CI, 1.54-2.15]). Hispanic (OR=1.59, [CI, 1.48-1.72]) and API (OR=1.32 [1.22-1.44]) patients also presented with higher odds of regional disease. Patients with the lowest SES presented with metastatic disease more often than those with the highest SES (OR=1.45 [CI, 1.16-1.82]). Those that were poor/uninsured and/or with Medicaid insurance had higher odds of presenting with metastatic disease as compared with those with private insurance (OR=2.41, [CI, 2.10-2.77]). Unadjusted overall survival rates were higher among API and Hispanic patients and lower among black patients (P<.001 vs white patients). Adjusted overall survival also showed a survival disadvantage for black patients (hazard ratio=1.4, [CI, 1.10-1.73]) and survival advantage for API patients (hazard ratio=0.83, [CI, 0.71-0.97]). In disease-specific survival analyses, when only those patients with metastatic disease were analyzed separately, black patients again had the lowest survival rates, and Hispanic/API patients had the highest survival rates (P<.04). CONCLUSION: Black patients and those with low SES have worse outcomes for thyroid cancer. API and Hispanic patients may have a protective effect on survival despite presenting with more advanced disease.
CONTEXT: Racial/ethnic minorities suffer disproportionate morbidity and mortality from chronic diseases. OBJECTIVE: Our objective was to assess racial and socioeconomic status (SES) disparities in well-differentiated thyroid cancer (WDTC) patients. DESIGN AND PARTICIPANTS: We conducted a retrospective cohort study on 25 945 patients with WDTC (1999-2008) from the California Cancer Registry (57% white, 4% black, 24% Hispanic, and 15% Asian-Pacific Islander [API]). MAIN OUTCOMES: We evaluated effect of race and SES variables on stage of cancer presentation and overall/disease-specific survival. RESULTS: Significant differences in stage of presentation between all racial groups were found (P<.001), with minority groups presenting with a higher percentage of metastatic disease as compared with white patients (black, odds ratio [OR]=1.36 with confidence interval [CI] 1.01-1.84; Hispanic, OR=1.89 [CI, 1.62-2.21], API, OR=1.82 [CI, 1.54-2.15]). Hispanic (OR=1.59, [CI, 1.48-1.72]) and API (OR=1.32 [1.22-1.44]) patients also presented with higher odds of regional disease. Patients with the lowest SES presented with metastatic disease more often than those with the highest SES (OR=1.45 [CI, 1.16-1.82]). Those that were poor/uninsured and/or with Medicaid insurance had higher odds of presenting with metastatic disease as compared with those with private insurance (OR=2.41, [CI, 2.10-2.77]). Unadjusted overall survival rates were higher among API and Hispanic patients and lower among black patients (P<.001 vs white patients). Adjusted overall survival also showed a survival disadvantage for black patients (hazard ratio=1.4, [CI, 1.10-1.73]) and survival advantage for API patients (hazard ratio=0.83, [CI, 0.71-0.97]). In disease-specific survival analyses, when only those patients with metastatic disease were analyzed separately, black patients again had the lowest survival rates, and Hispanic/API patients had the highest survival rates (P<.04). CONCLUSION: Black patients and those with low SES have worse outcomes for thyroid cancer. API and Hispanic patients may have a protective effect on survival despite presenting with more advanced disease.
Authors: Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Virginia G Kaklamani; Thomas J Hoffmann; Timothy A Thornton; Geoffrey Hayes; Rowan Chlebowski; Linda Van Horn; Christos Mantzoros Journal: Breast Cancer Res Treat Date: 2013-04-30 Impact factor: 4.872
Authors: Vickie L Shavers; Pebbles Fagan; Dionne Jones; William M P Klein; Josephine Boyington; Carmen Moten; Edward Rorie Journal: Am J Public Health Date: 2012-05 Impact factor: 9.308
Authors: Ian Mitchell; Edward H Livingston; Alice Y Chang; Shelby Holt; William H Snyder; Ildiko Lingvay; Fiemu E Nwariaku Journal: Surgery Date: 2007-12 Impact factor: 3.982
Authors: Gertrud S Berkowitz; Josephine Obel; Elena Deych; Robert Lapinski; James Godbold; Zhisong Liu; Philip J Landrigan; Mary S Wolff Journal: Environ Health Perspect Date: 2003-01 Impact factor: 9.031
Authors: David Luyimbazi; Rebecca A Nelson; Audrey H Choi; Lily Li; Joseph Chao; Virginia Sun; John B Hamner; Joseph Kim Journal: J Gastrointest Surg Date: 2014-11-25 Impact factor: 3.452
Authors: Evan F Garner; Ilan I Maizlin; Matthew B Dellinger; Kenneth W Gow; Melanie Goldfarb; Adam B Goldin; John J Doski; Monica Langer; Jed G Nuchtern; Sanjeev A Vasudevan; Mehul V Raval; Elizabeth A Beierle Journal: Surgery Date: 2017-06-08 Impact factor: 3.982